This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel).
Ticker(s): VRTX, CRSP, BLUEWho's the expert?
Institution: Cincinnati Children's Hospital Medical Center
- Medical Director, Division of Bone Marrow Transplantation and Immune Deficiency and Professor, UC Department of Clinical Pediatrics
- Treats 12 patients with cGVHD and is currently treating 4 patients with Rezurock(Belumosudil)
- Clinical interestes in bone marrow transplantation for primary immunodeficiencies, cord blood transplants, and leukemia
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
